Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature

References

• Reid IR. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol. 2011;40:1191. doi:10.1007/s00256-011-1164-9.
   PubMed Web of Science ®Google Scholar
• Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–1045. doi:10.4065/83.9.1032.
   PubMed Web of Science ®Google Scholar
• Pazianas M, Cooper C, Ebetino FH, Russell RGG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010;6:325–343. doi:10.2147/tcrm.s8054.
   PubMed Web of Science ®Google Scholar
• Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84:632–638. doi:10.1016/S0025-6196(11)60752-0.
   PubMed Web of Science ®Google Scholar
• Group S of UN (SUN) W. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Yeşiltaş YS, Gündüz AK. Idiopathic orbital inflammation: review of literature and new advances. Middle East Afr J Ophthalmol. 2018;25:71–80. doi:10.4103/meajo.MEAJO_44_18.
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–1565. doi:10.1210/jc.2009-1947.
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897–907. doi:10.1093/annonc/mdj105.
   PubMed Web of Science ®Google Scholar
• Orozco C, Maalouf NM. Safety of bisphosphonates. Rheum Dis Clin North Am. 2012;38:681–705. doi:10.1016/j.rdc.2012.09.001.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med. 2003;348:1187–1188. doi:10.1056/NEJM200303203481225.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135:219–222. doi:10.1016/S0002-9394(02)01840-8.
   PubMed Web of Science ®Google Scholar
• London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:43. doi:10.1186/1869-5760-3-43.
   PubMedGoogle Scholar
• Clark EM, Durup D. Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks? Ther Adv Musculoskelet Dis. 2015;7:11–16. doi:10.1177/1759720X14566424.
   PubMed Web of Science ®Google Scholar
• Patel DV, Horne A, House M, Reid IR, McGhee CNJ. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120:773–776. doi:10.1016/j.ophtha.2012.10.028.
   PubMed Web of Science ®Google Scholar
• Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49:103–110. doi:10.1016/j.bone.2011.01.003.
   PubMed Web of Science ®Google Scholar
• Peterson JD, Bedrossian JEH. Bisphosphonate-associated orbital inflammation—a case report and review. Orbit. 2012;31:119–123. doi:10.3109/01676830.2011.648818.
   PubMedGoogle Scholar
• Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012;184:E431–4. doi:10.1503/cmaj.111752.
   PubMed Web of Science ®Google Scholar
• French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina (Philadelphia, Pa). 2008;28:889–893. doi:10.1097/IAE.0b013e31816576ef.
   PubMed Web of Science ®Google Scholar
• Pazianas M, Clark EM, Eiken PA, Brixen K, Abrahamsen B. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res. 2013;28:455–463. doi:10.1002/jbmr.1783.
   PubMed Web of Science ®Google Scholar
• Afshari NA, Afshari MA, Foster CS. Inflammatory conditions of the eye associated with rheumatic diseases. Curr Rheumatol Rep. 2001;3:453–458. doi:10.1007/s11926-996-0017-3.
   PubMedGoogle Scholar
• Papapetrou PD. Bisphosphonate-associated adverse events. Hormones. 2009;8:96–110. doi:10.14310/horm.2002.1226.
   PubMedGoogle Scholar
• Borkar DS, Homayounfar G, Tham VM, et al. Association between thyroid disease and uveitis. JAMA Ophthalmol. 2017;135:594–599. doi:10.1001/jamaophthalmol.2017.1009.
   PubMed Web of Science ®Google Scholar
• Khan D, Ansar Ahmed S. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front Genet. 2015;6. doi:10.3389/fgene.2015.00236.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017;2017:2017. doi:10.1155/2017/3908061.
   Web of Science ®Google Scholar
• Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63:435–449. doi:10.1007/s00005-015-0344-z.
   PubMed Web of Science ®Google Scholar
• Figueroa-Vega N, Alfonso-Perez M, Benedicto I, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. Int J Clin Endocrinol Metab. 2010;95:953–962. doi:10.1210/jc.2009-1719.
   PubMed Web of Science ®Google Scholar
• Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250:1521–1526. doi:10.1007/s00417-012-2092-7.
   PubMed Web of Science ®Google Scholar
• Shen J, Li Z, Li W, et al. Th1, Th2, and Th17 cytokine involvement in thyroid associated ophthalmopathy. Dis Markers. 2015;2015:609593. doi:10.1155/2015/609593.
   PubMed Web of Science ®Google Scholar
• Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74:32–38. doi:10.1016/j.jbspin.2006.06.005.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737–738. doi:10.1056/NEJM199903043400914.
   PubMed Web of Science ®Google Scholar
• Cui Y, Shao H, Lan C, et al. Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol. 2009;183:560–567. doi:10.4049/jimmunol.0900241.
   PubMed Web of Science ®Google Scholar
• Liang D, Shao H, Born WK, O’Brien RL, Kaplan HJ, Sun D. Connection between γδ T-cell– and adenosine-mediated immune regulation in the pathogenesis of experimental autoimmune uveitis. Crit Rev Immunol. 2018;38:233–243. doi:10.1615/CritRevImmunol.2018026150.
   PubMed Web of Science ®Google Scholar
• Forrester JV, Klaska IP, Yu T, Kuffova L. Uveitis in mouse and man. Int Rev Immunol. 2013;32:76–96. doi:10.3109/08830185.2012.747524.
   PubMed Web of Science ®Google Scholar
• Liang D, Zuo A, Shao H, et al. Retinoic acid inhibits CD25+ dendritic cell expansion and γδ T-cell activation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2013;54:3493–3503. doi:10.1167/iovs.12-11432.
   PubMed Web of Science ®Google Scholar
• Sauty A, Pecherstorfer M, Zimmer-Roth I, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996;18:133–139. doi:10.1016/8756-3282(95)00448-3.
   PubMed Web of Science ®Google Scholar
• Thiébaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386–392. doi:10.1007/s002239900353.
   PubMed Web of Science ®Google Scholar
• Escobar LGG, Devia DG. Possible ocular adverse effects attributable to bisphosphonate therapy: two case reports. Revista Colombiana de Reumatología (English Edition). 2017;24:54–59. doi:10.1016/j.rcreue.2017.04.001.
   Google Scholar
• Pioli G. Bisphosphonates stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro. Calcif Tissue Int. 1990;46:A54.
   Google Scholar
• Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis. 2003;62:378. doi:10.1136/ard.62.4.378.
   PubMed Web of Science ®Google Scholar
• Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: a case report and review. South Med J. 2005;98:733–736. doi:10.1097/01.SMJ.0000152753.80490.9F.
   PubMed Web of Science ®Google Scholar
• Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics. 2012;6:89–99. doi:10.2147/BTT.S20677.
   PubMedGoogle Scholar